Pfizer Inc. $PFE Shares Purchased by Kestra Investment Management LLC

Key Points

• Kestra Investment Management LLC increased its stake in Pfizer Inc. by 38.6%, owning 81,290 shares valued at $2,060,000 by the end of the reporting period.
• Pfizer reported earnings per share of $0.78 for the last quarter, exceeding the consensus estimate of $0.58, with a revenue of $14.65 billion.
• The company recently announced a quarterly dividend of $0.43 per share, resulting in an annualized dividend of $1.72 and a dividend yield of 6.9%.

Kestra Investment Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 38.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,290 shares of the biopharmaceutical company's stock after acquiring an additional 22,619 shares during the period. Kestra Investment Management LLC's holdings in Pfizer were worth $2,060,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Triumph Capital Management boosted its holdings in Pfizer by 20.0% in the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 1,717 shares during the period. Centiva Capital LP boosted its holdings in Pfizer by 75.2% in the fourth quarter. Centiva Capital LP now owns 16,875 shares of the biopharmaceutical company's stock worth $448,000 after purchasing an additional 7,244 shares during the period. Finally, Fred Alger Management LLC boosted its holdings in Pfizer by 13.4% in the fourth quarter. Fred Alger Management LLC now owns 116,411 shares of the biopharmaceutical company's stock worth $3,088,000 after purchasing an additional 13,743 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 1.3%

Pfizer stock opened at $24.86 on Friday. The company has a 50-day simple moving average of $24.85 and a 200-day simple moving average of $24.35. The firm has a market capitalization of $141.31 billion, a P/E ratio of 13.22, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.